

X



[Make an Appointment](#)

[Back](#)

Office of Technology Development

Research Areas

Refer a Patient

Our mission, vision & core values

Leadership

History

Equality, diversity & inclusion

Annual report

Give to MSK

Explore our list of technologies available for licensing below, and filter by technology categories.

Some of our newest technologies may not appear in this list. To learn about recent developments, [contact any member of our staff](#) about your particular interests.

Search by keywords:

Enter a search term.

Search

Narrow your choices

+

52 Technologies found

SK2015-007

[3D Imaging by Interferometry Modulation](#)

Stage: design-prototype

Types: [Imaging](#), [Research Tools](#)

SK2022-004

[A Bispecific T-Cell Engager \(BiTE\) Against Oncogene HPVE7](#)

Stage: in-vitro

Types: [Therapeutics](#), [Cell/Gene therapies](#)

Indications: [Cancer](#)

SK2018-105, SK2020-043, SK2021-100

[A Fluorescent Peptide to Visualize Peripheral Nerve Anatomy During Surgery](#)

Stage: in-vitro

Types: [Imaging](#)

SK2018-127

[A Novel Multimeric IL15/ IL15R \$\alpha\$ -Fc Complex to Enhance Cancer Immunotherapy](#)

Stage: in-vitro

Types: [Therapeutics](#), [Antibodies/Antibody conjugates](#), [Cell/Gene therapies](#)

Indications: [Cancer](#), [Urinary System](#), [Pancreatic](#), [Melanoma](#), [Lung](#), [Infectious Disease](#)

SK2021-043

[A TCR Mimic Monoclonal Antibody Against "Public" Phospho-Neoantigens pIRS2](#)

Stage: in-vitro

Types: [Antibodies/Antibody conjugates](#)

Indications: [Cancer](#), [Ovarian](#), [Melanoma](#), [Colorectal](#), [Liver](#)

SK2018-039

[Anti-STEAP1 T-cell Engager Bispecific Antibody with Impressive Xenograft Data](#)

Stage: in-vitro

Types: [Antibodies/Antibody conjugates](#)

Indications: [Cancer](#), [Prostate](#), [Bones & Joints](#)

SK2017-097

[Bispecific Antibody Targeting T-cell TGFb Signaling for Cancer Immunotherapy](#)

Stage: in-vitro

Types: [Antibodies/Antibody conjugates](#)

Indications: [Cancer](#), [Breast](#)

MSK INTERNAL CODE SK2020-005

[Broad-spectrum Antiviral Activity of eIF4a Inhibitors](#)

Stage: in-vitro

Types: [Therapeutics](#)

Indications: [Infectious Disease](#)

SK2017-070

[Canine Anti-CD20 Antibody to Generate CAR T-cells for Lymphoma](#)

Stage: in-vitro

Types: [Cell/Gene therapies](#)

Indications: [Cancer](#), [Lymphoma](#)

SK2015-111

[CAR T-Cell Therapy with PD-1 Intrinsic Checkpoint Blockade](#)

Stage: clinical-development

Types: [Cell/Gene therapies](#)

Indications: [Cancer](#), [Lung](#), [Inflammatory/Immune Disease](#), [Transplantation](#)

[Load More](#)

PREVIOUS

[Success Stories](#)

NEXT

[Digital Health Projects](#)

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center